<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844361</url>
  </required_header>
  <id_info>
    <org_study_id>ITT2015006-EC-2</org_study_id>
    <nct_id>NCT02844361</nct_id>
  </id_info>
  <brief_title>Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia</brief_title>
  <acronym>BDH-WM03</acronym>
  <official_title>Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether autologous stem cell transplantation will
      improve the survival of patients with high-risk Waldenström macroglobulinemia, compared with
      conventional chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      WM patients with partial response after introduction chemotherapy will be recommended to
      adopt autologous stem cell transplantation or receive conventional chemotherapy (dependent on
      patient's choices). After transplantation or conventional chemotherapy, maintenance therapy
      with rituximab or thalidomide plus prednisone will be given for less than two years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress-free survival</measure>
    <time_frame>up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>autologous stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>autologous stem cell transplantation</intervention_name>
    <description>Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback</description>
    <arm_group_label>autologous stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional chemotherapy</intervention_name>
    <description>Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy</description>
    <arm_group_label>conventional chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 70 years&gt;=Aged &gt;=18 years

          2. diagnosed with high-risk LPL/WM according to the ISSWM criteria

          3. untreated or mild treated without standard regimens

          4. suitable for ASCT

          5. with life-expectancy more than 3 months.

        Exclusion Criteria:

          1. diagnosed with other malignancies outside B-NHL within one year(including active
             center neural system lymphoma)

          2. transformed lymphoma

          3. liver or renal function lesion unrelated to lymphoma

          4. serious complications such as uncontrolled diabetes, gastric ulcer or other serious
             angiocardiopathy determined by the physician

          5. HIV positive or active HBV infection or other uncontrolled systematic infection

          6. clinical central nervous dysfunction

          7. serious surgery within 30 days

          8. pregnancy or baby nursing period or un-contracepted child-bearing period woman; 9.
             allergy to the trail drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuhua Yi, Doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>blood disease hospital, Chinese Academic Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuhua Yi, Doc</last_name>
    <phone>86-22-23909106</phone>
    <email>yishuhua@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lugui Qiu, Doc</last_name>
    <phone>86-22-23909172</phone>
    <email>qiulg@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shuhua Yi</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhua Yi, Doc</last_name>
      <phone>86-22-23909106</phone>
      <email>yishuhua@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lugui Qiu, Doc</last_name>
      <phone>86-22-23909172</phone>
      <email>qiulg@ihcams.ac.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Yi Shuhua</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>high-risk</keyword>
  <keyword>ASCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>dependent on the local law</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

